Probiotic Yeasts Inhibit Virulence of Non -albicans Candida Species

• Published in: mBio Vol. 10; no. 5
• Main Authors: Kunyeit, Lohith, Kurrey, Nawneet K, Anu-Appaiah, K A, Rao, Reeta P
• Format: Journal Article
• Language: English
• Published: United States American Society for Microbiology 15.10.2019
• Subjects: Antifungal Agents - pharmacology; Biofilms - drug effects; Caco-2 Cells; Candida albicans - drug effects; Candida albicans - genetics; Humans; Probiotics - pharmacology; Therapeutics and Prevention; Virulence - genetics; Candida albicans; Caenorhabditis elegans; Candida auris; mixed-species Candida biofilm; probiotic yeasts; Candida krusei; Caco-2 cell monolayer; biofilm; plastic adhesion assay; Candida tropicalis; Candida glabrata; Candida parapsilosis
• ISSN: 2161-2129; 2150-7511
• DOI: 10.1128/mBio.02307-19

Systemic infections of species pose a significant threat to public health. Toxicity associated with current therapies and emergence of resistant strains present major therapeutic challenges. Here, we report exploitation of the probiotic properties of two novel, food-derived yeasts, (strain KTP) and (strain ApC), as an alternative approach to combat widespread opportunistic fungal infections. Both yeasts inhibit virulence traits such as adhesion, filamentation, and biofilm formation of several non- species, including , , , and as well as the recently identified multidrug-resistant species They inhibit adhesion to abiotic surfaces as well as cultured colon epithelial cells. Furthermore, probiotic treatment blocks the formation of biofilms of individual non- strains as well as mixed-culture biofilms of each non- strain in combination with The probiotic yeasts attenuated non- infections in a live animal. studies using suggest that exposure to probiotic yeasts protects nematodes from infection with non- strains compared to worms that were not exposed to the probiotic yeasts. Furthermore, application of probiotic yeasts postinfection with non- alleviated pathogenic colonization of the nematode gut. The probiotic properties of these novel yeasts are better than or comparable to those of the commercially available probiotic yeast , which was used as a reference strain throughout this study. These results indicate that yeasts derived from food sources could serve as an effective alternative to antifungal therapy against emerging pathogenic species. Non- -associated infections have emerged as a major risk factor in the hospitalized and immunecompromised patients. Besides, antifungal-associated complications occur more frequently with these non- species than with Therefore, as an alternative approach to combat these widespread non- -associated infections, here we showed the probiotic effect of two yeasts, (strain KTP) and (ApC), in preventing adhesion and biofilm formation of five non- strains, , , , , and The result would influence the current trend of the conversion of conventional antimicrobial therapy into beneficial probiotic microbe-associated antimicrobial treatment.